Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Idera Pharmaceuticals Inc (NASDAQ:IDRA)

2.50
Delayed Data
As of Sep 28
 +0.02 / +0.81%
Today’s Change
1.19
Today|||52-Week Range
4.42
-19.09%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$301.0M

Company Description

Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which is engaged in discovery, development and commercialization of novel nucleic acid therapeutics to treat patients with serious and life-threatening diseases. Idera's immunotherapy approach is based on the modulation of toll-like receptors (TLRs) while its third-generation antisense technology is designed to inhibit the production of disease-associated proteins by targeting RNA. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal and James B. Wyngaarden in May 25, 1989 and is headquartered in Cambridge, MA.

Contact Information

Idera Pharmaceuticals, Inc.
167 Sidney Street
Cambridge Massachusetts 02139
P:(617) 679-5500
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Vin MilanoPresident, Chief Executive Officer & Director
Louis J. ArcudiCFO, Treasurer & Senior Vice President-Operations
Sudhir A. AgrawalDirector & President-Research
Joanna C. HorobinChief Medical Officer & Senior Vice President
Mark J. CaseySecretary, Senior Vice President & General Counsel